TL;DR
- Autoimmune CAR-T has gone from niche experiment to strategic category in just a few years — with trial activity nearly zero before 2022 and now approaching 47 programs annually by 2025.
- Lupus leads the indication race (36.8% of programs), followed by MS and scleroderma, but the indications closest to pivotal proof are myasthenia gravis and scleroderma — because they offer cleaner endpoints, shorter timelines, and a stronger benefit-risk case for regulators.
- CD19 is the dominant target, reflecting the core thesis: lasting benefit in autoimmune disease requires resetting the B-cell compartment, not just suppressing it temporarily.
- The early evidence is promising — Cartesian’s Descartes-08 in MG leads on Intelligencia’s PTRS rankings, Cabaletta is building a multi-indication platform story, and Autolus is pushing into progressive MS. Markets are already repricing on early signals, with single data readouts moving stocks 25–112%.
- The open questions are safety durability, manufacturing scalability, and payer acceptance of a high upfront cost in exchange for long-term treatment reduction. Momentum is real. Approval-level proof is next.
Autoimmune CAR-T moves into the spotlight
CAR-T in autoimmune disease has moved from “interesting concept” to “strategic theme” in a remarkably short time. The catalyst has been a convergence of early clinical signals suggesting deep, durable immune reset is plausible in refractory patients, rising confidence that cell therapy delivery can expand beyond oncology centers, and investor and BD appetite for modalities that can plausibly change the slope of outcomes rather than incrementally improve them. Recent reporting has described an acceleration of experimentation and investment across autoimmune diseases as remissions accumulate and the category narrative hardens.
Distribution of Autoimmune Programs Across Modalities
Source: Intelligencia AI autoimmune clinical trial database · mAbs, CAR-T, and SMI programs by program start year
mAbs and SMIs remain the foundation of autoimmune R&D — but CAR-T has emerged as the fastest-rising third modality, driven by the belief that one-time or infrequent interventions could deliver longer treatment-free benefit than chronic regimens. The step-change post-2022 is not incremental; it reflects a category bet.
The modality shift no one expected this fast
Our autoimmune clinical trial dataset shows that mAbs and SMIs remain the dominant modalities — but CAR-T has gained serious ground only in the last few years. The shift is not gradual; it is step-change: CAR-T trials are near-zero through most of the timeline, then rise sharply after 2022. By 2024 and 2025, CAR-T initiations have accelerated to the point that they nearly match SMI initiations in annual volume, a rare pattern in autoimmune R&D where modality mix usually changes slowly.
The interpretation is not that mAbs and SMIs are being displaced in the near term — they remain the foundation. Rather, CAR-T has become the fastest-rising “third modality” in autoimmune development, driven by the belief that one-time or infrequent interventions could deliver longer treatment-free benefit than chronic regimens.
Distribution of CAR-T Cell Programs Across Indications
Source: Intelligencia AI autoimmune trial database · CAR-T programs only
Lupus leads by a wide margin because it is deeply B-cell and autoantibody mediated, has clear unmet need in refractory populations, and has generated high-profile early remission narratives. Multiple sclerosis and scleroderma follow as logical second and third poles, each with distinct biological rationale for an immune-reset strategy.
The indication map: Lupus first, then the high-need frontier
The skew toward lupus, MS, and scleroderma reflects where the “immune reset” thesis is easiest to justify — combining high unmet need with biologically coherent CAR-T rationale.
- Lupus (#1 · 36.8%) Lupus is the flagship because it is deeply B-cell/autoantibody-mediated in many severe patients, has clear unmet need in refractory populations, and has generated high-profile early remission narratives that are hard for the market to ignore.
- Multiple Sclerosis (#2 · 17.6%) MS is a logical second pole because B-cell biology is already validated clinically (anti-CD20 success), and there is persistent demand for approaches that can alter progression trajectories rather than simply control relapses.
- Scleroderma (#3 · 15.2%) Scleroderma attracts outsized CAR-T interest because it remains one of the hardest autoimmune diseases to treat meaningfully — high severity and limited options increase tolerance for innovative risk.
- Myasthenia Gravis (#4 · 8.0%) MG is strategically attractive because it is clinically measurable over months, and it is tightly linked to pathogenic antibodies — ideal for demonstrating whether immune reset translates into tangible clinical benefit.
Target Logic: The B-Cell Reset Playbook
Across autoimmune CAR-T trials, CD19 is the default, reflecting the core mechanistic thesis: durable benefit requires elimination or durable reconstitution of disease-driving B-cell compartments rather than temporary suppression. Where a second target appears, BCMA and CD20 are the most common complements.
BCMA BCMA aligns with plasma cell/antibody-producing biology — relevant in autoantibody-mediated disease states. Where long-lived plasma cells are a key driver of disease persistence, targeting BCMA alongside CD19 reflects a more complete approach to B-cell lineage depletion.
CD20 CD20 is clinically validated in autoimmune care pathways (RA, MS) and provides a familiar biological anchor. Its inclusion reflects the field’s effort to build on established mechanistic precedent while delivering a deeper and potentially more durable intervention.
In practical terms, target choice in autoimmune CAR-T is less about novelty and more about aligning engineering to a single dominant causal story: autoantibody-driven disease requires deeper immune remodeling than current chronic therapies deliver.
Why the pivotal push starts elsewhere
It looks counterintuitive at first: lupus and MS dominate overall CAR-T activity, yet myasthenia gravis (MG) and systemic sclerosis (scleroderma) are the indications that have progressed furthest into pivotal development. In practice, that ordering is strategically rational.
- MG — pivotal-friendly MG is “pivotal-friendly” because it is measurable, fast, and biologically coherent. Compared with lupus and MS, MG offers cleaner signal detection on shorter timelines. Clinical change can be quantified using widely accepted functional scales over weeks to months, not years.
- Scleroderma — severity justifies risk Systemic sclerosis has high morbidity and limited disease-modifying options. That creates a development environment where stakeholders may accept higher procedural and safety burden if the benefit is durable and clinically meaningful.
- Lupus & MS — large but harder to prove Lupus is notoriously heterogeneous, which raises noise and makes it harder to design a single pivotal story that satisfies regulators, payers, and clinicians. MS has longer timelines, slower-moving endpoints, and greater variability in baseline trajectory.
MG and scleroderma aren’t “more important” than lupus or MS — they’re more efficient proving grounds. They offer the best combination of biologic fit with the immune-reset thesis, measurable endpoints on feasible timelines, and a benefit-risk framing that can justify cell therapy complexity earlier in the lifecycle.
Where the Evidence Looks Strongest Today
- Cartesian Therapeutics – Descartes-08 (gMG, Phase 3) Intelligencia’s PTRS framework flags Descartes-08 as the most promising Phase 3 autoimmune CAR-T program today. In a Phase 2b randomized, placebo-controlled study in generalized myasthenia gravis, results reported clinically meaningful improvements at Month 4 across standard MG scales. A high proportion achieved sustained clinically meaningful response and a subset reached minimum symptom expression by Month 6, sustained through Month 12. Cartesian has since advanced Descartes-08 into Phase 3 (AURORA).
- Cabaletta Bio – CABA-201 (rese-cel) (Phase 1/2) Cabaletta’s effort is part of a broader “RESET” approach across multiple autoimmune diseases — designed to show that deep B-cell reset can be portable across indications. In 2024, Cabaletta reported early clinical responses across autoimmune cohorts including SLE/lupus nephritis, myositis, and systemic sclerosis, including cases of sustained improvements and reduced immunosuppressant dependence.
- Autolus – obe-cel in progressive MS (Phase 1) Autolus has initiated a Phase 1 trial of obe-cel in progressive MS, with the first patient dosed. The strategic logic is straightforward: MS already validates B-cell biology clinically, and progressive disease remains a high-value area where incremental benefit is difficult to achieve.
Market Sensitivity: The Autoimmune CAR-T Premium
One reason autoimmune CAR-T continues to attract attention is that early signals — even before pivotal trials — can trigger outsized market reactions. Nkarta’s shares surged 112% after the FDA cleared its IND to test a CD19-directed CAR-NK program in lupus. Kyverna’s shares climbed by more than 25% in early trading after the company released positive topline results in stiff person syndrome and outlined plans to pursue a BLA.
Momentum Is Real — Validation Is Next
The magnitude and speed of the post-2022 acceleration, combined with multiple sponsors building across lupus/MS/scleroderma/MG, supports that autoimmune CAR-T is more trend than fad. The critical long-term determinants will be:
- Durable safety and infection risk management over time in non-oncology, often younger patient populations
- Real-world scalability of cell therapy manufacturing and delivery beyond academic centers
- Whether payers accept the one-time cost in exchange for reduced long-term treatment burden
Turning Modality Momentum Into Disciplined Strategy
We support clinical, portfolio, and BD leaders navigating autoimmune CAR-T as a fast-moving, high-uncertainty category.
- For clinical development teams Use our benchmarks to compare trial architectures across autoimmune indications — so programs are designed to generate interpretable evidence under real-world heterogeneity.
- For portfolio strategists Use PTRS analytics and historical benchmarks to separate high-activity areas from high-probability areas — particularly important in autoimmune, where modality enthusiasm can outpace evidence maturity.
- For BD & licensing teams Use our landscape and precedent mapping to quantify competitive density by indication and target, identify where Phase 3 scarcity creates opportunity, and pressure-test differentiation claims against historical success patterns.
Bottom line
Autoimmune CAR-T is now a category shift in motion — momentum is real, validation is next. The winners will be sponsors who treat CAR-T not just as a modality bet, but as an evidence-building program grounded in indication-specific biology, measurable endpoints, and disciplined risk management.
